ACTA1 and cancer: While we found αSMA, collagen, and THY1 were most abundantly expressed at high levels in cancer tissues, these markers were also more commonly expressed in normal tissues, indicating increased potential for treatment-related adverse events if patients were treated with an αSMA-, collagen-, or THY1-targeting therapy.